Aspirin Resistance in Coronary Artery Disease

Phase 0 Completed 92 enrolled Vanderbilt University National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.

Timeline

Start: 2006-06
Primary completion: 2011-08
Completion: 2014-03

Outcome

Missed primary endpoint

paper Among the randomized subset, sTxB(2) levels were systematically higher among patients receiving enteric-coated aspirin. PMID 22311905 ↗

registry analysis (superiority test); Enteric-coated Aspirin vs Chewable Aspirin; p = 0.005; Wilcoxon rank-sum NCT00753935 ↗

Publications

Results Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, Boutaud O, Oates JA. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension. 2012 Mar;59(3):719-25. doi: 10.1161/HYPERTENSIONAHA.111.181404. Epub 2012 Feb 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aspirin	Small molecule	81 mg	—